Our Company Who we are Board of directors Team Stakeholders Our programs Pipeline Stage of Development Clinical Studies Patients invivo Media Contact
Clinical Studies Patients In vivo CAR-T Media Contact

Stage of Development

OC-1
AUTOLOGOUS CAR-T
Target
CD1a
Indication
T-ALL
Development
Preclinical
Clinical
OC-1d
AUTOLOGOUS CAR-T
Target
CD1a/CCR9
Indication
T-ALL
Development
Preclinical
Clinical
OC-2
AUTOLOGOUS CAR-T
Target
CD22
Indication
B-ALL
Development
Preclinical
Clinical
OC-3
ALLOGENEIC CAR-T
Target
N.D.
Indication
Any
Development
Preclinical
Clinical
OC-4
ALLOGENEIC CAR-T
Target
IL13a2/N.D.
Indication
GBM
Development
Preclinical
Clinical
OC-5
IN VIVO CAR-T
Target
N.D.
Indication
Solid tumours N.D.
Discovery
Development
Preclinical
N.D. = Not Disclosed